Sumitomo Corp., Summit Medi-Chem Release Fuel Cell Catalyst Capable of Using Ethanol.Tokyo, Japan, Aug 18, 2005 - (JCNN JCNN Japan Corporate News Network ) - Sumitomo Corp. (TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). : 8053) and its pharmaceutical and industrial chemical subsidiary Summit Medi-Chem have signed an exclusive sales agreement with Italian venture company ACTA SpA. Under the terms of the agreement, the Japanese companies will exclusively market a fuel cell catalyst developed by ACTA in Japan, Korea and Taiwan. ACTA has developed a technology to disperse ultra-fine metal catalyst grain (0.3-0.7nm in diameter), which achieves about the same galvanizing galvanizing, process of coating a metal, usually iron or steel, with a protective covering of zinc. Galvanized iron is prepared either by dipping iron, from which rust has been removed by the action of sulfuric acid, into molten zinc so that a thin layer of the zinc effect as conventional direct methanol cell catalysts by reducing use of platinum and ruthenium ruthenium (r  thē`nēəm), metallic chemical element; symbol Ru; at. no. 44; at. wt. 101.07; m.p. about 2,310°C;; b.p. about 3,900°C;; sp. gr. 12. to 0.2mg/cm2, the smallest amount ever achieved. The Italian company has also developed the world's first ethanol-based fuel cell catalyst that has used inexpensive cobalt, nickel and iron catalysts. Having the same components and being as freely transportable as alcohol, ethanol may be used for a fuel cell that will be used onboard. Direct ethanol cells will also be able to reduce greenhouse gas emissions since carbon dioxide carbon dioxide, chemical compound, CO2, a colorless, odorless, tasteless gas that is about one and one-half times as dense as air under ordinary conditions of temperature and pressure. , a byproduct of power generation using the direct ethanol cell, can be used as a bio ethanol material. The two Sumitomo group companies will ask ACTA to approach Japanese universities and research institutions for joint research. Sumitomo is aiming for sales of 5 million yen ($45,000) in fiscal 2005 and 5 billion ($45 mil) in fiscal 2008. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion